Oncology and the Sale of Hope
Oncology and the Sale of Hope
Civilizational diagnostic. First article of the Oncology as Supercherie series. See also: Big Pharma (the incentive architecture upstream), Psychiatry and the Soul (the structural twin — that article diagnoses a captured frame, this one a captured trade), Circumcision (consent at the other end of a life), Cancer — The Harmonism Protocol (the corrective at the individual scale), Dying Consciously, Sovereign Health, Wheel of Health.
A physician has one thing to give a person who is going to die, and it is not treatment. It is the truth, early enough to be used.
Everything else the profession offers a person with advanced cancer — the regimens, the ports, the scan intervals, the vocabulary of lines and cycles and responses — is downstream of that one transaction, and worth exactly what the transaction was worth. Where the truth was delivered, the treatments that follow are choices a person made about their own remaining life. Where it was withheld, every subsequent intervention is something done to a body whose owner was not in a position to refuse. The chemistry is the same in both cases. The act is not.
Advanced disease is where this is easiest to see. It is not where it stops. A woman told that a small thing was found in her breast and caught in time is moved through the same grammar — a word chosen for what it fails to carry, a benefit quoted in the form that makes it sound large, a harm folded into a phrase — and she is not dying, which means she has more to lose than the man on his fourth line. The scale changes. The trade does not.
What is traded is a single word. Treatment covers two different things and the room never separates them. Some of what oncology gives is matched to a specific exploitable particularity of one disease: a repair enzyme a tumour cannot make, a fusion protein that arrests a cell halfway through becoming a neutrophil, a kinase that drives one leukaemia and almost nothing else. Where the field has that, it sometimes cures, and the cure is real. Everything else is generic: cytotoxic agents deployed against diseases whose mechanism the field cannot reach, on the principle that cancer divides and poison kills dividing cells. That deployment buys weeks and takes years.
Both are called chemotherapy. Both arrive in the same voice, at the same desk, inside the same word. Concealing the seam between them is what the French calls a supercherie, a fraud that works by wearing the costume of the thing it is not, and its anatomy is what follows.
Not the molecule, not the market, not the research architecture: those are diagnosed at Big Pharma and The Captured Architecture, and the biology is held at Cancer — The Harmonism Protocol. What is diagnosed here is what the field says, to whom, and what it leaves out. It begins in the room, where a named person sitting across a desk is told something about their own body and their own remaining time, because that is the only place where oncology must convert what it knows into what it says. That gap is the subject.
What Is Owed
The oath that every medical school still recites resolves, in its most-quoted phrase, to first, do no harm. The profession receives it as a caution about technique — do not cut carelessly, do not exceed the tolerated dose, do not prescribe what interacts. Read that way it is risk management, and risk management is what a guild owes its insurer.
Harmonism reads the sentence as Dharma, articulated at Consent and the Sovereign Body — the physician’s alignment with Logos expressed in the single office where another human being places their body in another’s hands and has no capacity to verify what is done with it. Asymmetry is the whole moral structure here. The patient cannot evaluate the claim; the patient can only trust or refuse, and refusal without information is not a choice but a coin-toss. Everything the physician owes flows from that asymmetry, and none of it is discharged by technical care alone. A perfectly administered infusion given to a person who does not know what it is for delivers harm competently. Nothing about the precision of the delivery converts it into good medicine.
And the harm a physician can do is not only chemical. Time is the one substance a dying person has least of, and it is the substance oncology spends most freely. A person with eleven months left who is routed into a treatment circuit — infusion suites, blood draws, scan cycles, the recovery days between, the hospitalisations for neutropenic fever — has not been given anything. They have had their remaining life converted into a schedule administered by someone else. Whether that conversion was worth it is a question only they can answer, and they can only answer it if someone tells them the numbers.
Two things are owed, then, before any treatment is named. What is happening in the body, in the patient’s own language, using the actual word. And what the proposed intervention will and will not change, expressed in the units the patient will live in — months, not percentages; function, not response rates. Both are owed in the first conversation, unasked, before the question of what to do is raised at all. A person cannot consent to a plan whose purpose has not been stated.
Neither is delivered. Not occasionally, not in the difficult cases. In the modal case.
The Sentence That Is Never Said
The first thing to go is the vocabulary. Consultations that concern a malignancy routinely proceed without the word cancer being spoken, and without the word tumour either. What is spoken instead is lesion, mass, shadow, nodule, growth, something we want to keep an eye on, abnormal cells, a spot on the scan. Each of these is technically defensible and each is chosen because it is not the word. The oncologist does not lie. The oncologist selects, from a range of accurate terms, the one that leaves the patient’s understanding closest to where it was.
The second thing to go is the prognosis. There is a specific sentence, and it is short: this disease is not curable, and the treatment I am offering does not aim at cure. In advanced solid-tumour oncology this sentence is true in the overwhelming majority of consultations, and it is very largely unsaid. What is said instead runs to we have some very good options, many patients do extremely well on this, let’s see how you respond, one step at a time. Every clause is defensible. None of them contains the information.
Researchers have measured the consequences, and the measurement is unambiguous. Weeks and colleagues, publishing in the New England Journal of Medicine in 2012, surveyed patients receiving chemotherapy for metastatic lung and colorectal cancer — patients whose disease was, in every case, incurable, and whose treatment was palliative by design. Sixty-nine percent of the lung-cancer patients and eighty-one percent of the colorectal patients did not report understanding that chemotherapy was not at all likely to cure them. These were not people who had declined to ask. They were people in active treatment, several conversations deep, who had come away believing they were being cured. One finding opens the whole structure, and it sits buried in the same paper’s secondary analysis. Patients who rated their oncologist’s communication most favourably were the ones most likely to hold the false belief. Those who scored their physician’s communication below perfect were roughly half as likely to be mistaken about their prognosis — the odds ratio for inaccurate belief ran to 1.90 in the direction of the highest-rated communicators. The physician who conveys the optimistic picture is experienced by the patient as the better communicator. The physician who says the sentence is experienced as worse at their job.
Nothing in this is a failure of communication skill. What the room performs is a market clearing. The euphemism is not an accident that better training would correct; it is the product the room selects for, rewarded by the patient in the satisfaction survey, rewarded by the institution in the retention figures, rewarded by the specialty in the referral pattern. The lie is load-bearing.
A 2024 cohort in Japan measured the same gap from both sides at once. Two hundred patients with pretreated advanced non-small-cell lung cancer, and their oncologists, asked independently whether incurability had been disclosed. Oncologists reported disclosing it to 92.5 percent. Patients reported hearing it from 69 percent. Agreement between the two accounts, measured by kappa, was 0.19 — barely above chance. Nearly four in ten of the patients still expected cure. And those holding that expectation were significantly less likely to receive specialist palliative care, which is the concrete cost: the false belief does not merely sit in the mind, it routes the person away from the care that would have helped them. Physicians in that study were not lying about having said it. They very likely had said something. What the kappa of 0.19 measures is the distance between a sentence uttered in clinical register, hedged and softened and folded into a discussion of options, and a sentence a frightened person can receive. Oncology has resolved that distance in its own favour and calls the resolution disclosure.
The word was never spoken, because the room rewards its absence.
The Arithmetic of Significance
The second withholding concerns the numbers, and here the profession has built an entire grammar for making small quantities sound large.
Three devices do most of the work. First, relative risk. A regimen that lifts two-year survival from four percent to six percent has produced a two-point absolute gain and a fifty-percent relative improvement, and it is the second figure that reaches the patient, the press release, and the conference slide. A patient hears that the drug improves survival by half. What the drug does is move ninety-four people out of a hundred to ninety-two.
Second, the median. Trials report median overall survival, and improvements are reported as differences between medians — a gain of 2.3 months, of 6 weeks, of 1.4 months. In the consultation these become it extends life. They are not lies. They are also not what any person hears in the phrase extends life, which imports an image of years. When a drug’s contribution to a life is six weeks, and roughly half of that six weeks will be spent in the treatment circuit and in recovery from it, the honest translation is that the drug purchases a few weeks of a diminished state at the far end. That translation is almost never performed at the desk.
Third, the surrogate endpoint. Increasingly, cancer drugs are licensed and marketed on progression-free survival or response rate rather than on whether patients live longer. Progression-free survival measures the interval before a scan shows growth. It is not a measure of life. A drug can hold a tumour radiographically static, satisfy the endpoint, secure the approval, and confer no additional day of survival — and the correlation between surrogate gains and overall survival, examined systematically, is weak across most tumour types. Davis, Naci and colleagues, reviewing every cancer indication approved by the European Medicines Agency between 2009 and 2013 in the BMJ, found that of sixty-eight approvals, twenty-four showed a survival benefit at the time of licensing and seven showed a quality-of-life benefit. After a median 5.4 years of follow-up, roughly half remained unproven on either measure.
Most cancer drugs enter the market without evidence that they extend or improve life, and a substantial fraction never acquire it.
Aggregate contribution is the figure the field prefers not to discuss. Morgan, Ward and Barton, publishing in Clinical Oncology in 2004, estimated the contribution of curative and adjuvant cytotoxic chemotherapy to five-year survival across adult malignancies in two national populations: 2.3 percent in Australia, 2.1 percent in the United States. Defenders answer that the figure is diluted by cancers in which chemotherapy is not used, and that restricting the denominator to patients who actually receive it lifts the number to five or six percent. The most honest sentence in the entire subsequent exchange came from one of the paper’s own critics: at 2% or 6%, surely the message is the same.
The Victories, and What They Prove
Against all of that the field sets a short list, produced whenever the aggregate figure is raised, and produced as though producing it settled the matter. Cisplatin combination regimens in germ-cell tumours. Childhood acute lymphoblastic leukaemia. Hodgkin lymphoma. Choriocarcinoma.
An honest reckoning adds what came after, which the list’s critics usually omit. Imatinib in chronic myeloid leukaemia: United States mortality falling at more than twelve percent a year from 1997, Japanese mortality at more than twenty percent a year from 2001, arriving by 2008 at roughly thirty percent of the 1993 rate — while incidence in both countries was falling, which excludes the overdiagnosis artefact by construction. And acute promyelocytic leukaemia, where all-trans retinoic acid combined with arsenic trioxide cures the large majority of a disease that used to kill in weeks. Harmonism holds these as real. The instrument that convicts mammography at Cancer — The Harmonism Protocol — population mortality read against incidence, which neither lead-time bias nor overdiagnosis can counterfeit — is the same instrument that acquits here, and a test trusted when it condemns cannot be refused when it acquits. Hodgkin belongs on the list by convention rather than by demonstration; the population-mortality series that would confirm it has not been read, and it is held open rather than claimed.
One methodological reservation stands, and it is narrower than the one usually made. Einhorn’s 1977 paper, from which the germ-cell claim is dated, was not randomised. It was measured against historical controls, in a decade when surgical technique, computed-tomography staging and the tumour-marker assays all improved at once. After this, therefore because of this is not a standard of proof, and a field that demands randomised evidence before conceding anything to a dietary intervention has forfeited the right to accept a before-and-after curve as demonstration when the agent is its own. The germ-cell cure survives anyway, on dose-response within the treatment era and on mechanism. What does not survive is the double standard.
So grant every entry at full valuation. They still do no work the field asks of them, and they do something else instead.
Look at what they have in common. Germ-cell tumour cells under-express ERCC1-XPF, the endonuclease that repairs the DNA crosslinks cisplatin creates; transfect the enzyme back in and the cells stop dying — a laboratory manipulation that abolishes the effect by restoring the proposed cause. Imatinib blocks one fusion kinase, BCR-ABL, present in that leukaemia and in almost nothing else. All-trans retinoic acid does not kill the promyelocyte at all. It releases a transcriptional block, and the cell finishes becoming the neutrophil it had been arrested halfway toward. Childhood leukaemia, Hodgkin and choriocarcinoma are rapidly dividing and non-epithelial, and choriocarcinoma secretes a marker that makes remission a number rather than an impression.
Every victory is a lock that had a key.
Not one of those keys fits breast, lung, colon, prostate or pancreas. Epithelial carcinomas, which constitute the actual burden, express ERCC1-XPF normally, carry no single fusion driver, and divide no faster than the gut lining the drug destroys on its way through. Oncology’s own molecular biology explains, in precise terms, why its successes cannot generalise.
It generalises from them anyway. Specific victories become a general warrant, and the warrant licences cytotoxic deployment across the ninety-seven percent where no key exists and the gain, where there is one, is weeks. That short list was excluded by name from the 2.3 percent — that figure is what remains after the field’s best cases have been set aside — so it cannot rebut an arithmetic it was never inside.
Two further facts sit underneath the list, and the field raises neither.
Arsenic trioxide reached the clinic from the Chinese materia medica. White arsenic — pīshuāng in the older Chinese pharmacopeia — was worked into a leukaemia treatment during the 1970s by Zhang Tingdong and colleagues at the First Affiliated Hospital of Harbin Medical University, from the recipes of a countryside practitioner. Western replication followed two decades later, and the English-language literature has never once cited Zhang’s original papers. The cleanest cure in the whole of oncology came out of a folk tradition, was refined outside the industry, and entered the Western pharmacopeia with its discoverer erased.
And melanoma, the showpiece of the immunotherapy era, turned before the drugs arrived. The mortality curve reaches its inflection around 2001 in the United States and 2004 in Australia, roughly a decade ahead of the first checkpoint inhibitor, and the researchers who measured it attribute the turn to the sun-protection campaigns of the preceding thirty years. The steeper fall after 2014 is very likely the drugs. The turn was prevention, and prevention is not what gets named in the consultation.
A field with a handful of victories that treats four hundred diseases as though it had won them has not made a scientific error.
It has made a sale.
You Caught It Early
Everything so far concerns people who are going to die of the disease. Most people handed a cancer diagnosis are not in that position, and the same architecture operates on them, with one difference that runs the wrong way. They have more to lose.
Begin with the diagnosis that manufactures the disease. Ductal carcinoma in situ names a population of abnormal cells inside a milk duct rather than a tumour, is found almost entirely by screening, and enters the register as stage 0 breast cancer — after which it is treated as cancer, with surgery, frequently radiation, and sometimes the removal of the breast. Narod and colleagues followed 108,196 American women diagnosed with it between 1988 and 2011. Breast-cancer mortality at twenty years was 3.3 percent. Radiotherapy after lumpectomy halved invasive recurrence in the same breast, from 4.9 percent to 2.5, and moved mortality from 0.9 percent to 0.8, which is to say not at all. Mastectomy did not improve survival over lumpectomy either.
And of the women who did die of breast cancer, 54.1 percent had suffered no invasive recurrence in the breast beforehand — meaning the local treatment was aimed at something other than what killed them.
Read that sequence again, because it contains the whole of early-stage oncology in one cohort. A screening programme finds a lesion. That lesion is named with the word for the disease. Naming it produces an operation, and sometimes the loss of a breast, in a woman whose twenty-year risk of dying of breast cancer stood at around three percent before anyone touched her. The operation does not move that number.
Then the adjuvant sale, which is the larger one. After an early tumour is removed, chemotherapy is offered against the possibility that cells escaped before the operation. Nobody can see those cells. No test finds them, no scan shows them, and there is no way to know, in any individual woman, whether anything is there to treat. So the treatment goes to everyone in the category, on the arithmetic that some fraction of them harbour something — which is exactly why the absolute gain is small. Most of the treated have nothing to treat and take the full toxicity regardless. Oncology measured this itself and published the answer. TAILORx enrolled 10,273 women with hormone-receptor-positive, node-negative breast cancer and randomised the intermediate-risk group between endocrine therapy alone and endocrine therapy plus chemotherapy. At nine years, invasive disease-free survival ran 83.3 percent against 84.3. Overall survival ran 93.9 percent against 93.8. Adding cytotoxic chemotherapy to the standard treatment of the most common presentation of the most common cancer in women moved overall survival by one-tenth of a percentage point, in the wrong direction, inside the noise. Around seventy percent of women in that category could be spared it entirely.
They had not been spared it. They had been receiving it for two decades, and the trial establishing that they did not need it reported in 2018.
The genomic assays that now identify who benefits — Oncotype DX, MammaPrint — were absorbed by the field as innovation, and to a point the field is entitled to that, because they work and they do spare people. They are also a measurement of the preceding error. An instrument telling you that seventy percent of the treated derived nothing is an instrument telling you what was done to that seventy percent in the years before it existed.
None of which empties the adjuvant setting. In stage III colon cancer the MOSAIC trial added oxaliplatin to fluorouracil and produced an absolute six-year overall survival gain of 2.5 percentage points — real, small, and precisely the kind of number a person can weigh when it is handed to them. In stage II the same addition produced no overall survival benefit at all. Both figures exist. Only the first is a reason to treat, and neither is what the patient hears, which is that chemotherapy improves survival in colon cancer.
Beneath all of it sits the sentence that closes most early-stage consultations. We think we got it all, but we’d like to do some chemotherapy to be safe. It is a confession of not knowing, delivered in the register of prudence, and it is received as prudence because the accurate version — I cannot tell whether anything is left, neither can anyone else, and what I am proposing will harm you for certain and may help you not at all — is never the version spoken.
The screening apparatus that produces these patients in the first place is treated below and at Cancer — The Harmonism Protocol.
The Grammar of War
The vocabulary that replaces the withheld one is martial, and the substitution is not decorative.
Cytotoxic agents are therapeutic weapons. The available regimens are the arsenal. Treatment is aggressive — a word used as praise. The sequence of failed regimens is lines, as in a defensive position falling back. The patient responds, fails, or progresses, and the grammar of that last verb is worth sitting with: the disease advances, and the sentence puts the patient in the subject position. The patient failed third-line therapy. The drug did not fail. The patient did.
The obituary completes the structure. A person dies after a long and courageous battle with cancer, and the metaphor has already assigned the outcome. Where death is a lost battle, survival is a won one, and the difference between them is located in the fighter. This is why patients apologise to their oncologists. It is why families describe a relative as a fighter in the weeks when fighting is precisely what should be set down. And it is why declining treatment is heard, by everyone in the room including the patient, as giving up — a moral failure rather than a clinical judgement, and one the person will be asked to justify to their children. Refusal, in this grammar, is desertion. Seeking a second opinion outside the paradigm is defection. And the person most disadvantaged by the metaphor is exactly the person the metaphor is aimed at: someone frightened, recently diagnosed, with no independent means of evaluating any claim being made, who now understands that the only available identity is fighter and that the alternative is quitter.
The same grammar disposes of the harms. Adverse effects are toxicity, and toxicity is manageable, and regimens are well tolerated — tolerated by a cohort, measured on a scale that counts grade 3 and grade 4 events and calls everything beneath them acceptable. What sits beneath the threshold, uncounted: mouth and gut mucosa stripped raw, peripheral neuropathy that does not resolve when the drug stops, the cognitive dulling patients name chemo brain and the literature took decades to concede, cachexia, marrow suppression and the infections that follow, cardiotoxicity from the anthracyclines, permanent infertility in the young, and secondary malignancies arriving years later from the treatment itself. Each of these is documented. Each is in the prescribing information. Very few of them are said aloud, in plain words, in the conversation where the person is deciding. The word poison is available, precise, and unused. Cytotoxic means cell-killing; the agents are selected for a therapeutic window between the rate at which they kill malignant cells and the rate at which they kill the patient’s own, and the window is narrow by design. A person told this is a poison, calibrated to damage you slightly less than it damages the tumour would have received an accurate description and would be positioned to decide. Instead they are told about a therapy.
Nor is the tax disclosed where the treatment works. Men cured of testicular cancer — the field’s showpiece — carry second solid cancers at 1.4 to 1.9 times the population rate and cardiovascular disease at 1.4 to 7.1 times, with the standard regimen carrying a 5.7-fold coronary-artery-disease risk. Thirty-eight percent have persistent renal dysfunction at five years. One in five reports symptomatic hearing loss, rising to half above a cumulative cisplatin dose of 400 mg/m². Twenty to forty percent carry peripheral neuropathy; over a third are hypogonadal by a median age of thirty-eight; and the probability of fathering a child falls from a hundred percent at two cycles to forty-eight above 850 mg. Every one of those numbers is dose-dependent, which is to say the field knows the shape of the curve it is putting a young man on. He is told he is being cured. He is not told what he is buying it with.
The Vendor of Hope
The French has the phrase exactly: vendeur d’espoir. What oncology sells, at the point of sale, is hope. Treatment is the delivery mechanism.
Commercial architecture makes this legible. When first-line therapy fails, there is second-line. When second-line fails, third. In many tumour types the response rates at third and fourth line fall into the single digits and the median survival gains vanish into the confidence interval, and the regimens are offered anyway, because the alternative is a conversation in which nothing is offered and that conversation is the one the entire structure exists to avoid. When the lines are exhausted, there is the clinical trial — presented as access to the frontier, and functioning, for the great majority of enrolled patients at that stage, as one more delivery of hope with a data-collection function attached.
Incentives run the same direction at every level. In the American system the buy-and-bill arrangement pays oncology practices a percentage margin on the drugs they purchase and administer, which makes the more expensive regimen the more remunerative one; when Medicare compressed those margins in 2005, prescribing patterns shifted in response, which is the cleanest available demonstration that the financial gradient reaches the prescription pad. Hospital oncology services are among the highest-margin lines in the institution. And none of this requires a corrupt individual anywhere in the chain. The oncologist offering fourth-line therapy is very often acting from something that feels like compassion — the wish not to abandon, the wish to have something to give. The structure has arranged matters so that compassion and revenue point the same way, which is the most efficient corruption available, because it never has to be chosen.
Cost lands on the household, and it is measurable. Ramsey and colleagues at the Hutchinson Institute, linking a regional cancer registry to federal bankruptcy records, found that cancer patients who filed for bankruptcy were roughly eighty percent more likely to die than those who did not; for colorectal cancer the figure was two and a half times. Around three percent of cancer patients go bankrupt. Read causally it is not complicated: the money runs out, and then the person does. A family is left having spent its house on six weeks that were sold as good options.
The invoice continues to the death certificate. The person who was never told is billed to the end for a hope they were never in a position to price.
What the End Actually Costs
The defence of all of this is that hope has value — that patients want to fight, that taking hope away is itself a harm, that the alternative to treating is abandonment. It is the profession’s most sincere argument and the only one that deserves an answer rather than a diagnosis.
The answer is that it has been tested, twice, and it failed both times.
Prigerson and colleagues, in JAMA Oncology in 2015, followed patients with metastatic cancer and a life expectancy of six months or less, comparing those who received palliative chemotherapy with those who did not. Adjusted survival was not associated with chemotherapy use — the treatment bought no additional time. Quality of life near death was worse in the treated group. And the effect concentrated in the patients with the best baseline performance status: among those still well enough to function, chemotherapy was associated with markedly worse quality of death, at an odds ratio of 0.35. People with the most life left to lose were the ones who lost the most of it. In the patients already debilitated, the treatment made no measurable difference either way. Which is to say: it did nothing for the sickest and harmed the strongest.
The constructive half of the finding is older and better known, and the field has had it since 2010. Temel and colleagues, in the New England Journal of Medicine, randomised patients with metastatic non-small-cell lung cancer either to standard oncologic care or to standard care with early integrated palliative care — meaning, in practice, honest prognostic conversation from the point of diagnosis. Patients in the palliative-care group had better quality of life. They had less clinically significant depression: sixteen percent against thirty-eight. They received substantially less aggressive care at the end — thirty-three percent against fifty-four, where aggressive means chemotherapy within a fortnight of death, or hospice entered too late to matter.
And they lived longer. Median survival 11.6 months against 8.9.
Told the truth early, given less treatment, they got nearly three additional months. This inverts the profession’s central justification completely. The honest conversation is not the compassionate alternative to effective treatment. In the trial that tested it, the honest conversation was the more effective treatment — and it worked by causing patients to accept less of what oncology sells.
Sixteen years on, early palliative integration remains the exception rather than the standard, in a field that describes itself as evidence-based.
The Diagnostic That Harms
The withholding is not confined to prognosis. It extends backward into the diagnostic apparatus, where interventions are presented as neutral acts of looking and are nothing of the kind. The full treatment is held at Cancer — The Harmonism Protocol; the structural point belongs here.
A woman entering a mammography programme is not told that the best synthesis of the randomised trials finds roughly one breast-cancer death averted per two thousand women screened over a decade, against roughly ten healthy women overdiagnosed — cut, irradiated, or given chemotherapy for lesions that would never have threatened them — and around two hundred put through the fear and follow-up of a false positive. She is not told that the procedure delivers ionising radiation to breast tissue on a repeating schedule, or that its sensitivity is lowest in exactly the dense tissue most at risk. She is told that early detection saves lives, which is a slogan rather than a finding.
A patient sent for a PET scan is not told that the entire test rests on injecting a radioactive glucose analogue and watching the tumour consume it faster than any healthy tissue — that oncology built its most sensitive imaging on the fact that cancer runs on sugar, and then built none of its treatment on taking the sugar away. Nor is the radiation burden named: a single PET-CT can deliver the equivalent of several years of background exposure, and it is repeated on a schedule to monitor progress.
A patient consenting to a needle biopsy is not told that passing a needle through a solid tumour can displace malignant cells along the tract, or that the procedure breaches the fibrin and stromal architecture the body uses to wall the tumour off. Conventional literature holds tract seeding to be rare and minor. Rare and minor is a claim about a population; the person on the table is not a population, and they were not given the number.
None of these procedures is presented as an intervention. All of them are.
Surgery, and the Window That Is Not Innocent
One conventional intervention survives the audit, and it should be named plainly, because a diagnosis that condemns everything condemns nothing.
Where a tumour is localised, accessible, and caught early, surgical excision removes it. That is a real act with a real result, and no metabolic, immune, or biophysical protocol substitutes for it in that situation. Harmonism holds surgery as legitimate — and holds it as one intervention alongside the metabolic, antiparasitic, oxidative and biophysical modalities set out in Part II of the protocol, not as the redeeming contribution of a field that otherwise poisons. The surgeon who removes an early tumour is doing what a physician is for. What divides the legitimate from the rest is not the conventional-unconventional line but whether the intervention removes or reverses the disease.
Surgery is legitimate. It is not innocent, and the profession’s silence about why is of a piece with everything above.
The perioperative window is itself a metastatic risk, through mechanisms that are now well characterised. A surgical wound triggers a transient but profound suppression of natural-killer and cytotoxic T-cell function at precisely the moment cells are mobilised. Tissue injury releases IL-6, TNF-alpha and VEGF into circulation, and the resulting inflammatory and angiogenic milieu favours seeding. Manipulation of the tumour sheds circulating tumour cells, including clusters whose metastatic potential exceeds that of single cells by orders of magnitude. Wound-healing signalling drives TGF-beta and the epithelial-mesenchymal transition, conferring invasiveness on cells that did not have it. Neutrophil extracellular traps, thrown out as part of the wound response, capture circulating cells and shelter them. And dormant micrometastases wake. Krall and colleagues, in Science Translational Medicine in 2018, showed the systemic wound-healing response driving the outgrowth of distant, immune-controlled tumours in mouse models of dormancy — surgery elsewhere in the body awakening what the immune system had been holding. Retsky and Demicheli read the bimodal relapse peak in breast cancer the same way: an early recurrence spike at roughly eighteen months that fits surgical triggering better than it fits natural history, and which perioperative ketorolac — a cheap, off-patent anti-inflammatory given at induction — appears to flatten, most markedly in the triple-negative subgroup.
Two consequences follow, and neither is drawn by the field.
First: the perioperative window is a terrain intervention, not a logistical interval. Metabolic preparation before the incision, anti-inflammatory and immune support across it, and monitoring after — the operative expression of the same architecture the protocol builds — belong to the surgery as much as the anaesthetic does. That the standard pathway treats those days as empty is the same blindness that treats the scan as looking.
Second, and never once offered to a patient. Where a tumour is borderline resectable, or where its position makes excision mutilating, the metabolic press-pulse — sustained ketosis, timed extended fasts driving the glucose-ketone index into the range where the fermentative cell is most exposed, glutamine restriction, hyperbaric oxygen at the end of the fast — applies real pressure to tumour mass before the operation. Reduce the burden, and the resection is smaller, the margin cleaner, the mutilation less, and in some presentations the question of whether to cut at all is reopened. Oncology has a name for shrinking a tumour before surgery. It is neoadjuvant, and it means chemotherapy or radiation, invariably. That a metabolic protocol might occupy the same slot has not been tested at scale, because there is nothing in it to sell — and the patient who might have chosen it is not told the slot exists.
The full protocol is at Part II. What belongs here is the shape of the omission: a person facing an operation is told about the operation, and not about the fortnight on either side of it, where a considerable part of the outcome is decided.
The Violation
Set the elements beside each other and they stop looking like a series of communication failures. They compose a single act, and the act has a name.
A person is told their body has a mass. They are not told the disease cannot be cured. They are offered a therapy described as aggressive, in a grammar where declining it is surrender and their family is listening. Benefit is quoted in relative terms or in a surrogate endpoint, and the six weeks it actually represents are never converted into the unit they will live in. Harms are compressed into manageable toxicity. The bill runs to the end. And the alternative that the field’s own randomised evidence shows produces better quality of life, less depression, and nearly three additional months of survival is not raised, because raising it requires saying the sentence.
At the other end of the disease the same act wears better clothes. A woman is told that something was found early and that she is fortunate. She is not told that the lesion may never have troubled her, that the operation proposed will not move her mortality, or that the chemotherapy offered afterward left overall survival exactly where it was in the trial the field itself ran. She consents to being saved. What she is consenting to has not been described to her.
None of that is care rendered imperfectly under difficult conditions. A body is worked upon without the consent of the person inside it — consent being impossible where the information required to give or withhold it was never supplied. Circumcision names the same violation at the beginning of a life, where the argument turns on an infant who cannot yet speak. Here the person can speak. They are simply not given what they would need in order to have anything to say.
Primum non nocere is not a professional courtesy that a specialty may interpret in the light of its own difficulties. Harmonism holds it as Dharma — one of the clearest instances in any vocation of what alignment with Logos demands of a person occupying a position of asymmetric power. To take a frightened human being’s last year and spend it, without telling them the price or the purchase, inflicts harm for gain. Bedside manner does not reach it, and the karmic weight of an act is not lightened by the sincerity with which it was performed, nor by an entire profession performing it in unison.
The individual clinician is mostly not the villain here, and the diagnosis is not improved by pretending otherwise. Oncologists are trained inside this grammar, evaluated by metrics that reward it, and surrounded by colleagues who share it; many are exhausted, many are kind, and many have never once been shown what an honest consultation looks like, because their own teachers did not model it. The architecture is what is indicted. But an architecture is built and maintained by the people who work inside it, and every consultation is a place where one of them can say the sentence.
The Consultation That Would Be Honest
The corrective is not complicated, which is itself part of the indictment. Four sentences, in the first conversation, unprompted.
You have cancer, and here is where it is. This disease is not curable, and nothing I can offer aims at cure. What I can offer might add roughly this many weeks, on average, and here is what those weeks will cost you in function and in time spent here rather than at home. You do not have to take it, and if you decline, I will still look after you.
The early-stage version is four sentences also, and it is the one that is never said at all. This is what was found, and here is how likely it was ever to harm you. The operation I am proposing moves that likelihood by this much. The treatment after it moves it by this much more, and here is what it will cost you across the year you spend receiving it. You can also watch it, and here is what watching looks like.
A person given four sentences of either kind is in possession of their own situation. What they do next is theirs. Some will take the regimen, with clear eyes, for reasons that are entirely their own — a wedding to reach, a grandchild due. That is sovereignty exercised, and it deserves support rather than the quiet condescension the alternative medicine world sometimes offers people who choose conventional treatment.
Others will do what the field never suggests and what the evidence above quietly recommends. They will decline the circuit and take the time. And that time is not an empty consolation but the interval in which the actual work becomes possible: the metabolic press-pulse and sustained ketosis, the repurposed antiparasitics, the oxidative and biophysical modalities, the enzyme and immune architecture, the supplement stack read continuously by Monitor — the whole structure of Part II of the protocol, which is not the fallback for people who have run out of options but the only approach that operates on what produced the disease. Clearing the burden, feeding the terrain, restoring the vessel. Some recover. More recover than the field’s dismissal admits, and less reliably than the healing world’s enthusiasm claims, and the honest tier for each modality is named in the protocol itself rather than smoothed over.
And for those the terrain work does not save, the time is still theirs. Dying Consciously holds what that means — that a death approached with knowledge, in one’s own house, among one’s own people, with affairs closed and things said, is not a lesser outcome than a death in an infusion suite pursuing a fourth line but a better one, at the register where these things are actually measured. The field cannot see that register, and so it sells the alternative until the last invoice.
The sovereign practitioner does not arrive at this consultation unprepared. The whole architecture of Sovereign Health is the preparation — the habit of reading one’s own body through Monitor, the refusal to accept a claim because a credential accompanied it, the willingness to ask an oncologist is this curable, what is the absolute gain in months, what is the surrogate endpoint here, and what happens if I do nothing. Four questions, set out with their arithmetic worked at The Sovereign Consultation. An honest physician will answer them and be glad to be asked. What the answers reveal, and what the room does when they are asked, is the whole diagnosis in miniature.
The territory of a person’s death was never the profession’s to hold. It was taken, sold back in weekly instalments, and the receipt was a euphemism.
Take it back, early, while the time is still worth having.
See also: Consent and the Sovereign Body, The Sovereign Consultation, Big Pharma, The Captured Architecture, Psychiatry and the Soul, Circumcision, Vaccination, Cancer — The Harmonism Protocol, Sovereign Health, Root Cause of Disease, Dying Consciously, Wheel of Health, Monitor, Wheel of Harmony, Logos, Dharma, Sovereignty